inclisiran Leqvio
Selected indexed studies
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. (N Engl J Med, 2020) [PMID:32187462]
- Inclisiran: First Approval. (Drugs, 2021) [PMID:33620677]
- Inclisiran: A Review in Hypercholesterolemia. (Am J Cardiovasc Drugs, 2023) [PMID:36869996]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. (2020) pubmed
- Inclisiran: First Approval. (2021) pubmed
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. (2024) pubmed
- Inclisiran: A Review in Hypercholesterolemia. (2023) pubmed
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. (2020) pubmed
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. (2023) pubmed
- PMID:39869730 (2024) pubmed
- Inclisiran (Leqvio) monotherapy for LDL-cholesterol reduction. (2025) pubmed
- Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. (2025) pubmed
- Inclisiran (Leqvio) for LDL-cholesterol lowering. (2022) pubmed